ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 3
Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.